Advertisement

Adjuvante Chemotherapie beim Mammakarzinom

  • B. Teleky
  • R. Jakesz
Part of the Angewandte Onkologie book series (AONKOLOGIE)

Zusammenfassung

Der Brustkrebs ist das häufigste Karzinom und die häufigste Todesursache der Frau [1]. Diese Tatsache ist für Onkologen eine Herausforderung, nach effektiven Therapiemaßnahmen zu suchen. Trotz der Fortschritte in Diagnose (Gesundenuntersuchung, Routinemammographie ab dem 35. Lebensjahr) und der primären Behandlung mit Operation, Nachbestrahlung und systemischer stadiengerechter Adjuvanstherapie wird etwa die Hälfte aller Patienten die ersten l0 Jahre nicht überleben [2–5]. Die adjuvante Therapie wird bei Patienten mit Mammakarzinom nach erfolgter chirurgischer Primärtherapie mit zytotoxischen Substanzen durchgeführt oder besteht aus einer antihormonellen Behandlung. Das Ziel ist es also, durch übliche Diagnoseschritte nicht nachweisbare subklinische, okkulte Metastasen zu eliminieren, um so bei akzeptabler Lebensqualität die Überlebenszeit zu verlängern. Die Wahrscheinlichkeit des Vorhandenseins solcher subklinischer Metastasen hängt von spezifischen Prognosekriterien ab.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Howell A, Morrison JM (1983) Adjuvant chemotherapy for operable breast cancer. Rev Endocr Rel Cancer [Suppl] 13: 19Google Scholar
  2. 2.
    Fisher B, Slack NH, Bross ID, et al (1969) Cancer of the breast: size of neoplasm and prognosis. Cancer 24: 1071PubMedCrossRefGoogle Scholar
  3. 3.
    Cancer Research Campaign Trial for Early Breast Cancer (1980) A detailed update at the tenth year. Cancer Research Campaign Working Party. Lancet 11: 55Google Scholar
  4. 4.
    Brinkley D, Haybittle JR (1975) The curability of breast cancer. Lancet 1: 95CrossRefGoogle Scholar
  5. 5.
    Mueller CB, Jeffries W (1975) Cancer of the breast. Its outcome as measured of death. Ann Surg 182: 334Google Scholar
  6. 6.
    Henderson JC, Canellos GP(1980) Cancer of the breast: the past decade. N Engl J Med 302: 17PubMedCrossRefGoogle Scholar
  7. 7.
    Skipper HE (1971) Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28: 1479PubMedCrossRefGoogle Scholar
  8. 8.
    Mendelsohn ML (1960) The growth fraction: a new concept applied to tumors. Science 132: 1496Google Scholar
  9. 9.
    Martin DS (1981) The scientific basis for adjuvant chemotherapy. Cancer Treat Rev 8: 169PubMedCrossRefGoogle Scholar
  10. 10.
    Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727PubMedGoogle Scholar
  11. 11.
    Goldie JH, Coldman Ai (1984) The genetic origin of drug resistance in neoplasms: implication for systemic therapy. Cancer Res 44: 3643PubMedGoogle Scholar
  12. 12.
    McGuire WL, Clark GM (1989) Prognosis in breast cancer. In: Senn HJ, Goldhirsch A, Gelber RD, et al (eds) Adjuvant therapy of primary breast cancer. Springer, Berlin Heidelberg New York Tokyo, p 170CrossRefGoogle Scholar
  13. 13.
    Say CC, Donegan WL (1974) Invasive carcinoma of the breast: prognostic significance of tumor size and involved axillary lymph nodes. Cancer 34: 468PubMedCrossRefGoogle Scholar
  14. 14.
    McGuire WL (1975) Current status of estrogen receptors in human breast cancer. Cancer 36: 638PubMedCrossRefGoogle Scholar
  15. 15.
    Fisher B (1972) Surgical adjuvant therapy for breast cancer. Cancer 30: 1556PubMedCrossRefGoogle Scholar
  16. 16.
    Stenkvist B, Bengtsson E, Dahlquist B, et al (1982) Predicting breast cancer recurrence. Cancer 50: 2884PubMedCrossRefGoogle Scholar
  17. 17.
    Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359PubMedCrossRefGoogle Scholar
  18. 18.
    Parl FF, Dupont WD (1982) A retrospective cohort study of histologic risk factors in breast cancer patients. Cancer 50: 2410PubMedCrossRefGoogle Scholar
  19. 19.
    Reiner A, Kolb R, Reiner G, et al (1987) Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer. J Cancer Res Clin Oncol 113: 285PubMedCrossRefGoogle Scholar
  20. 20.
    Bianco G, Alavaikko M, Ojala A, et al (1984) Estrogen and progesterone receptors in breast cancer: relationship to tumor histopathology and survival of patients. Anticancer Res 4: 383Google Scholar
  21. 21.
    Dressler LG, Seamer L, Owens MA, et al (1987) Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry. Cancer Res 47: 5294PubMedGoogle Scholar
  22. 22.
    Dressler LG, Seamer L, Owens MA, et al (1988) DNA flow cytometry and prognostic factors in 1.331 frozen breast cancer specimens. Cancer 61: 420PubMedCrossRefGoogle Scholar
  23. 23.
    Slamon DJ, Clark GM, Wong SG, et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177PubMedCrossRefGoogle Scholar
  24. 24.
    Zeilinger R, Kury F, Czerwenka K, et al (1989) HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4: 109Google Scholar
  25. 25.
    Carter CL, Allen C, Henson DE (1989) Relation in tumor size, lymph node status and survival in 24.740 breast cancer cases. Cancer 63: 181PubMedCrossRefGoogle Scholar
  26. 26.
    Jakesz R, Dittrich Ch, Holzner JH, et al (1985) Die Bedeutung von Östrogen-and Progesteronrezeptoren für die Rezidiv-and Gesamtüberlebensrate von Patienten mit primärem Mammakarzinom — Ergebnisse einer prospektiv randomisierten Studie. In: Jonat W, Kaufmann M, Kublin F, et al (Hrsg) Aktuelle Onkologie 16. Zuckschwerdt, München Bern Wien, S 19Google Scholar
  27. 27.
    Clark GM, Dressler LG, Owens MA, et al (1989) Prediction of relapse or survival in patients with node negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627PubMedCrossRefGoogle Scholar
  28. 28.
    Tandon AK, Clark GM, Chamness GC, et al (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297PubMedCrossRefGoogle Scholar
  29. 29.
    Thorpe SM, Rochefort H, Garcia M, et al (1989) Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6009Google Scholar
  30. 30.
    Spyratos F, Maudelonde T, Brouillet JP, et al (1989) Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet ii: 1115Google Scholar
  31. 31.
    Early Breast Cancer Trial ists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319: 1681CrossRefGoogle Scholar
  32. 32.
    Bonadonna G, Valagussa P, Zambetti M, et al (1987) Milan adjuvant trials for stage I—II breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, p 211Google Scholar
  33. 33.
    Jakesz R, Kolb R, Reiner G, et al (1987) Adjuvant chemotherapy in node negative breast cancer patients. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, p 223Google Scholar
  34. 34.
    Fisher B, Redmond C, Dimitro NV, et al (1989) A randomized clinical trial evaluating sequential melphalan and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen receptor negative tumors. N Engl J Med 320: 473PubMedCrossRefGoogle Scholar
  35. 35.
    Mansour E, Gray R, Shatila A, et al (1989) Efficacy of adjuvant chemotherapy in high risk node-negative breast cancer. An intergroup study. N Engl J Med 320: 485Google Scholar
  36. 36.
    Houghton J, Baum M, Nissen-Meyer R, et al (1989) Is there a role for perioperative adjuvant cytotoxic therapy in the treatment of early breast cancer. In: Senn HJ, Goldhirsch A, Gelber RD, et al (eds) Adjuvant therapy of primary breast cancer. Springer, Berlin Heidelberg New York Tokyo (Recent Results in Cancer Research, p 54 )CrossRefGoogle Scholar
  37. 37.
    Senn HJ, Barett-Mahler R (1987) Update of Swiss adjuvant trials with LMF and CMF in operable breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, p 243Google Scholar
  38. 38.
    Fisher B, Redmond CK, Wolmark N, et al (1987) Long term results from NSABP trials of adjuvant therapy for breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, p 283Google Scholar
  39. 39.
    Morrison JM, Howell A, Grieve RJ, et al (1987) The West Midlands Oncology Association trials of adjuvant chemotherapy for operable breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, p 311Google Scholar
  40. 40.
    Jakesz R (1985) Adjuvante Chemotherapie beim Mammakarzinom. Bericht von and Kommentar zur „NIH-Consensus-Development-Konferenz“, Bethesda, Maryland, USA, 9.-11. September 1985. Wien KIin Wochenschr 97: 825Google Scholar
  41. 41.
    Nissen-Meyer R, Kjellgren K, Malmio K, et al (1978) Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41: 2088Google Scholar
  42. 42.
    The Ludwig Breast Cancer Study Group (1989) Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320: 491CrossRefGoogle Scholar
  43. 43.
    The Ludwig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319: 677CrossRefGoogle Scholar
  44. 44.
    Bonadonna G, Valagussa P, Rossi A, et al (1985) Ten year experience with CMF based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95PubMedCrossRefGoogle Scholar
  45. 45.
    Henderson IC, Gelman RS, Harris JR, et al (1986) Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1: 95PubMedGoogle Scholar
  46. 46.
    Hryniuk WM, Levine MN, Levin L (1986) Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1: 87PubMedGoogle Scholar
  47. 47.
    Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281PubMedGoogle Scholar
  48. 48.
    Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162PubMedGoogle Scholar
  49. 49.
    Hryniuk WM (1989) Correlation of dose intensity and prognosis in adjuvant chemotherapy: an extended controversy. In: Senn HJ, Goldhirsch A, Gelber RD, et al (eds) Adjuvant therapy of primary breast cancer. Springer, Berlin Heidelberg New York Tokyo (Recent Results in Cancer Research, p 17 )CrossRefGoogle Scholar
  50. 50.
    Glucksberg H, Rivkin SE, Rasmussen S, et al (1982) Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with axillary nodes. A Southwest Oncology Group study. Cancer 50: 423Google Scholar
  51. 51.
    Rivkin SE, Green S, Metch B, et al (1989) Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10 year results of a Southwest Oncology Group study. J Clin Oncol 7: 1229PubMedGoogle Scholar
  52. 52.
    Weiss RB, Tormey DC, Holland F, et al (1982) A randomized trial of postoperative five versus three drug chemotherapy after mastectomy: a Cancer and Leukemia Group B ( CALGB) study. Rec Res Cancer Res 80: 170Google Scholar
  53. 53.
    Buzdar AU, Hortobagyi GN, Smith TL, et al (1988) Adjuvant therapy of breast cancer with or without additional treatment with alternative drugs. Cancer 62: 2098PubMedCrossRefGoogle Scholar
  54. 54.
    Peng-Tiam ANG, Buzdar AU, Smith TL, et al (1989) Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 7: 1677Google Scholar
  55. 55.
    Fisher B, Redmond C, Wickerham DL, et al (1989) Doxorubicin-containing regimes for the treatment of stage II breast cancer: the NSABP experience. J Clin Oncol 7: 572PubMedGoogle Scholar
  56. 56.
    Mathe G, Plagne R, Morice V, et aI (1987) Consistencies and variations of observation during serial analyses of a trial of adjuvant chemotherapy in breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, p 271Google Scholar
  57. 57.
    Perloff M, Norton L, Korzun A, et al (1986) Advantage of an adriamycin (A) combination plus halotestin (H) after initial cyclophosphamide, methotrexate, 5fluorouracil, vincristine and prednison (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc ASCO 5: 70 (abstract)Google Scholar
  58. 58.
    Misset JL,, de Vassal F, Jasmis C et al (1984) Five year results of the French adjuvant trial for breast cancer comparing CMF to a combination of adriamycin (ADM), vincristin (VCR), cyclophosphamide (PM) and 5-fluorouracil (5-FU). In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune & Stratton, Orlando, p 243Google Scholar
  59. 59.
    Buzdar AV, Kau SW, Smith TL, et al (1989) Ten year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12: 123PubMedCrossRefGoogle Scholar
  60. 60.
    Fisher B, Fisher ER, Redmond C (1986) Ten years results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard ( L-PAM) in the management of primary breast cancer. J Clin Oncol 4: 929Google Scholar
  61. 61.
    Rosner F, Carey RW, Zarrabi MH (1978) Breast cancer and acute leukemia: report of 24 cases and review of the literature. Am J Hematol 4: 151PubMedCrossRefGoogle Scholar
  62. 62.
    Ersher WB, Robins HI, Davis HL, et al (1982) Emergence of acute non-lymphocytic leukemia in breast cancer patients. Am J Med Sc 248: 23CrossRefGoogle Scholar
  63. 63.
    Howell P, Glick JH, Bucolo A, et aI (1981) Cytogenetic studies of bone marrow in breast cancer patients after adjuvant chemotherapy. Cancer 48: 667CrossRefGoogle Scholar
  64. 64.
    Koyama H, Wada T, Takahashi Y, et al (1980) Surgical adjuvant chemotherapy with mitomycin C and cyclophosphamide in Japanese patients with breast cancer. Cancer 46: 2373PubMedCrossRefGoogle Scholar
  65. 65.
    Kapadia SB, Krause JR, Ellis LD, et al (1980) Induced acute non-lymphocytic leukemia following long-term chemotherapy: a study of 20 cases. Cancer 45: 1315PubMedCrossRefGoogle Scholar
  66. 66.
    Fisher B, Rockette H, Fisher ER, et al (1958) Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation. J Clin Oncol 3: 1640Google Scholar

Copyright information

© Springer-Verlag/Wien 1992

Authors and Affiliations

  • B. Teleky
  • R. Jakesz

There are no affiliations available

Personalised recommendations